Abstract #2498
Tumor infiltration beyond contrast enhancement and FLAIR hyperintensity at autopsy predicts survival in glioblastoma patients
Samuel Bobholz1, Allison Lowman2, Michael Brehler2, Savannah Duenweg1, John Sherman1, Fitzgerald Kyereme2, Elizabeth Cochran3, Dylan Coss3, Jennifer Connelly4, Wade Mueller5, Mohit Agarwal2, Anjishnu Banerjee6, and Peter LaViolette2,7
1Biophysics, Medical College of Wisconsin, Milwaukee, WI, United States, 2Radiology, Medical College of Wisconsin, Milwaukee, WI, United States, 3Pathology, Medical College of Wisconsin, Milwaukee, WI, United States, 4Neurology, Medical College of Wisconsin, Milwaukee, WI, United States, 5Neurosurgery, Medical College of Wisconsin, Milwaukee, WI, United States, 6Biostatistics, Medical College of Wisconsin, Milwaukee, WI, United States, 7Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, United States
Synopsis
This study compared autopsy tissue samples to clinical MRI from glioblastoma (GBM) patients to assess the effects of tumor outside of T1-contrast enhancement and FLAIR hyperintensity on clinical characteristics and outcomes. Non-enhancing tumors were more frequent amongst patients who had a history of bevacizumab treatment and no history of Tumor Treating Fields treatment. Additionally, non-enhancing tumors were associated with shorter overall survival times. These results suggest that non-enhancing tumors have clinically significant correlates and may result in worse survival outcomes for GBM patients.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
